Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem is poised for success with strong financials, promising study results, and strategic collaborations. With a diversified pipeline targeting critical pathways in cancer, the company has the potential for significant growth in the market. Additionally, their focus on partnerships for commercialization and combination treatments show a commitment to increasing the effectiveness of their treatments and potentially expanding their market reach.

Bears say

Verastem is facing challenges in its RAMP 205 trial, with positive but mixed results from its phase 1b/2a expansion cohort in metastatic pancreatic cancer showing a 52% cORR, 68% 6-month PFS rate, and 86% 6-month OS rate, but with still limited follow-up on mPFS/mOS. The company's management is pinning its hopes on potential collaborations and the potential role of avutometinib/defactinib in metastatic pancreatic cancer, but the assumed launch of these drugs in 2025 with a high cost of therapy and limited potential peak penetration rates does not bode well for the company's financial outlook in the near term.

Verastem (VSTM) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.